Goeddel David V's Form 4 filing
NGM Biopharmaceuticals Inc (NGM) · filed May 19, 2022
- Accession no.
- 0000899243-22-018846
- Filed
- May 19, 2022
- Trade date
- May 17-18, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market purchases total $2.02M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Goeddel David VCIK 0001182464 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 17, 2022 | Common Stock | PPurchaseAcquired | +86,110 | $13.42F1 | +$1,155,596.2 | 1,336,461 | Indirect | |
| May 17, 2022 | Common Stock | PPurchaseAcquired | +2,939 | $13.42F1 | +$39,441.38 | 45,610 | Indirect | |
| May 18, 2022 | Common Stock | PPurchaseAcquired | +60,583 | $13.20F4 | +$799,695.6 | 1,397,044 | Indirect | |
| May 18, 2022 | Common Stock | PPurchaseAcquired | +2,067 | $13.20F4 | +$27,284.4 | 47,677 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.90 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.98 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Referenced by the price of 2 transactions in Table I.